HLA risk markers for chronic myelogenous leukemia in Eastern Canada

References

• Sawyers C L. Chronic myeloid leukemia. N Engl J Med 1999; 340: 1330–1340
   PubMed Web of Science ®Google Scholar
• Pinilla-Ibarz J, Cathcart K, Scheinberg D A. CML vaccines as a paradigm of the specific immunotherapy of cancer. Blood Rev 2000; 14: 111–120
   PubMed Web of Science ®Google Scholar
• Schmitt M, Li L, Giannopoulos K, Chen J, Brunner C, Barth T, et al. Chronic myeloid leukemia cells express tumor-associated antigens eliciting specific CD8+ T-cell responses and are lacking costimulatory molecules. Exp Hematol 2006; 34: 1709–1719
   PubMed Web of Science ®Google Scholar
• Bocchia M, Wentworth P A, Southwood S, Sidney J, McGraw K, Scheinberg D A, et al. Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules. Blood 1995; 85: 2680–2684
   PubMed Web of Science ®Google Scholar
• Bosch G J, Joosten A M, Kessler J H, Melief C J, Leeksma O C. Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide. Blood 1996; 88: 3522–3527
   PubMed Web of Science ®Google Scholar
• Clark R E, Dodi I A, Hill S C, Lill J R, Aubert G, Macintyre A R, et al. Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. Blood 2001; 98: 2887–2893
   PubMed Web of Science ®Google Scholar
• Norbury L C, Clark R E, Christmas S E. b3a2 BCR-ABL fusion peptides as targets for cytotoxic T cells in chronic myeloid leukaemia. Br J Haematol 2000; 109: 616–621
   PubMed Web of Science ®Google Scholar
• Butt N M, Rojas J M, Wang L, Christmas S E, Abu-Eisha H M, Clark R E. Circulating bcr-abl-specific CD8+ T cells in chronic myeloid leukemia patients and healthy subjects. Haematologica 2005; 90: 1315–1323
   PubMed Web of Science ®Google Scholar
• Hester J P, Rossen R, Trujillo J, McCredie K B, Freireich E J. Frequency of HLA antigens in chronic myelocytic leukemia. South Med J 1977; 70: 691–693
   PubMed Web of Science ®Google Scholar
• Ruuska P, Silvennoinen-Kassinen S, Timonen T, Tiilikainen A. Chronic myelocytic leukaemia: HLA association and decreased erythrocyte C3b receptor expression. Clin Exp Immunol 1985; 59: 300–304
   PubMed Web of Science ®Google Scholar
• Oguz F S, Kalayoglu S, Diler A S, Tozkir H, Sargin D, Carin M, et al. HLA system affects the age-at-onset in chronic myeloid leukemia. Am J Hematol 2003; 73: 256–262
   PubMed Web of Science ®Google Scholar
• Posthuma E F, Falkenburg J H, Apperley J F, Gratwohl A, Roosnek E, Hertenstein B, et al. HLA-B8 and HLA-A3 coexpressed with HLA-B8 are associated with a reduced risk of the development of chronic myeloid leukemia. The Chronic Leukemia Working Party of the EBMT. Blood 1999; 93: 3863–3865
   PubMed Web of Science ®Google Scholar
• Posthuma E F, Falkenburg J H, Apperley J F, Gratwohl A, Hertenstein B, Schipper R F, et al. HLA-DR4 is associated with a diminished risk of the development of chronic myeloid leukemia (CML). Chronic Leukemia Working Party of the European Blood and Marrow Transplant Registry. Leukemia 2000; 14: 859–862
   PubMed Web of Science ®Google Scholar
• Rosas-Cabral A, Irigoyen L, Alvarado L, Vela-Ojeda J, Ayala-Sanchez M, Tripp-Villanueva F, et al. HLA CW3 and HLA CW4 have a protective effect on acquisition of chronic myeloid leukemia on Mexican patients. Rev Invest Clin 2003; 55: 423–428
   PubMed Web of Science ®Google Scholar
• Amirzargar A A, Khosravi F, Dianat S S, Alimoghadam K, Ghavamzadeh F, Ansaripour B, et al. Association of HLA class II allele and haplotype frequencies with chronic myelogenous leukemia and age-at-onset of the disease. Pathol Oncol Res 2007; 13: 47–51
   PubMed Web of Science ®Google Scholar
• Khosravi F, Amirzargar A, Sarafnejad A, Nicknam M H, Alimoghadam K, Dianat S, et al. HLA class II allele and haplotype frequencies in Iranian patients with leukemia. Iran J Allergy Asthma Immunol 2007; 6: 137–142
   PubMed Web of Science ®Google Scholar
• Chhaya S U. Human leukocyte antigens in Indian patients with chronic myeloid leukemia. Leuk Lymphoma 2006; 47: 291–295
   PubMed Web of Science ®Google Scholar
• Li D, Xi B, Liu H Y, Yu Y. Association of gene HLA-class I with leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2005; 13: 563–566
   PubMedGoogle Scholar
• Miao K R, Pan Q Q, Xue M, Fan S, Wang X Y, Pan M, et al. Human leukocyte antigens in 295 Chinese patients with chronic myeloid leukemia. Leuk Lymphoma 2007; 48: 2152–2156
   PubMed Web of Science ®Google Scholar
• Tian H, Zhou S Y, Liu Z H, Fu Y G, Lu F J, Lin J H, et al. Association of HLA-DPB1 alleles with chronic myelogenous leukemia in southern Chinese Hans. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2003; 11: 266–268
   PubMedGoogle Scholar
• Yasukawa M, Ohminami H, Kojima K, Inokuchi K, Nishimura Y, Fujita S. Analysis of HLA-DRB1 alleles in Japanese patients with chronic myelogenous leukemia. Am J Hematol 2000; 63: 99–101
   PubMed Web of Science ®Google Scholar
• Garcia-Lora A, Algarra I, Garrido E. MHC class I antigens, immune surveillance, and tumour immune escape. J Cell Physiol 2005; 195: 346–355
   Web of Science ®Google Scholar
• Dorak M T, Chalmers E A, Gaffney D, Wilson D W, Galbraith I, Henderson N, et al. Human major histocompatibility complex contains several leukemia susceptibility genes. Leuk Lymphoma 1994; 12: 211–222
   PubMed Web of Science ®Google Scholar
• Corsten P G, Blight C E, Riddell D C, Hamilton D C, Cole D E. Molecular diagnosis of cystic fibrosis in Maritime Canada. Clin Invest Med 1994; 17: 1–8
   PubMed Web of Science ®Google Scholar
• Greene-Davis S T, Neumann P E, Mann O E, Moss M A, Schreiber W E, Welch J P, et al. Detection of a R173W mutation in the porphobilinogen deaminase gene in the Nova Scotian “foreign Protestant” population with acute intermittent porphyria: a founder effect. Clin Biochem 1997; 30: 607–612
   PubMed Web of Science ®Google Scholar
• Greer W L, Riddell D C, Gillan T L, Girouard G S, Sparrow S M, Byers D M, et al. The Nova Scotia (type D) form of Niemann-Pick disease is caused by a G3097–>T transversion in NPC1. Am J Hum Genet 1998; 63: 52–54
   PubMed Web of Science ®Google Scholar
• StatView for Windows version 4.57. Abacus Concepts Inc. 1992–1996, Berkeley, CA
   Google Scholar
• Rice W R. Analyzing tables of statistical tests. Evolution 1989; 43: 223–225
   PubMed Web of Science ®Google Scholar
• Review Manager (RevMan) [computer program]. Version 4.2 for windows. the Nordic Cochrane Centre, the Cochrane Collaboration, Copenhagen 2003
   Google Scholar
• CPRA calculator [Internet]. United Network for Organ Sharing, Available from: http://www.unos.org/resources/frm_CPRA_Calculator.asp?index=78 [cited 20 Oct 2008]
   Google Scholar
• High Resolution HLA Alleles and Haplotypes in the US Population [Internet]. National marrow donor program, Available from: http://bioinformatics.nmdp.org/HLA/Haplotype_Frequencies/DOCS/ABDRB1.pdf [cited 20 Oct 2008]
   Google Scholar
• Ebeling S B, Ivanov R, Hol S, Aarts T I, Hagenbeek A, Verdonck L F, et al. HLA-DRB1*16-restricted recognition of myeloid cells, including CD34+ CML progenitor cells. Br J Haematol 2003; 121: 721–729
   PubMed Web of Science ®Google Scholar
• Pawelec G, Wagner W. Is HLA-DR4 or the HLA-DRB1*0402 allele associated with decreased risk for CML?. Leukemia 2001; 15: 192–193
   PubMed Web of Science ®Google Scholar
• Yasukawa M, Ohminami H, Kojima K, Hato T, Hasegawa A, Takahashi T, et al. HLA class II-restricted antigen presentation of endogenous bcr-abl fusion protein by chronic myelogenous leukemia-derived dendritic cells to CD4(+) T lymphocytes. Blood 2001; 98: 1498–1505
   PubMed Web of Science ®Google Scholar
• Yasukawa M, Ohminami H, Kaneko S, Yakushijin Y, Nishimura Y, Inokuchi K, et al. CD4+ cytotoxic T cell clones specific for bcr-abl b3a2 fusion peptide augment colony formation by chronic myelogenenous leukemia cells in a b3a2-specific and HLA-DR-4 restricted manner. Blood 1998; 92: 3355–3361
   PubMed Web of Science ®Google Scholar
• Sun J Y, Senitzer D, Forman S J, Chatterjee S, Wong K K, Jr. Identification of new MHC-restriction elements for presentation of the p210(BCR-ABL) fusion region to human cytotoxic T lymphocytes. Cancer Immunol Immunother 2003; 52: 761–770
   PubMed Web of Science ®Google Scholar
• MacIntyre A R, Christmas S E, Clarke R E. The influence of class II HLA type on the lymphoproliferative response of normal donors to a bcr-abl fusion peptide. Exp Hematol 1996; 24: 1307–1311
   PubMed Web of Science ®Google Scholar